Regeneron: PCSK9s Drowning In Paperwork

A common problem is plaguing both Regeneron Pharmaceuticals Inc. and Amgen Inc. – paperwork, specifically, the abundance of paperwork patients and physicians need to fill out to prescribe a PCSK9 inhibitor.

Regeneron expressed its frustrations about the process now in place that is limiting patient access to the class of drugs during its first quarter call on May 5.

"Unfortunately, due to unprecedented strict utilization management criteria and very tedious prior authorization paperwork and documentation that the pharmacy benefits...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Metabolic Disease-Focused Poxel Teeters On The Edge

 

The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.

UCB Takes A Bow as Bimzelx HS Launch Achieves Lift-Off

 
• By 

The Belgian company has raised its outlook for full-year sales following a strong launch for Bimzelx in hidradenitis suppurativa in the first half of 2025.

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By 

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By 

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

More from Scrip

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By 

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By 

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

 

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.